Kodiak reports Phase 3 Zenkuda AMD trial results
Share
Kodiak Sciences (NASDAQ:KOD) reported that Zenkuda and tabirafusp-ted met primary vision endpoints in the Phase 3 DAYBREAK trial evaluating treatments for wet age-related macular degeneration.
Kodiak Sciences (NASDAQ:KOD) reported that Zenkuda and tabirafusp-ted met primary vision endpoints in the Phase 3 DAYBREAK trial evaluating treatments for wet age-related macular degeneration.
Kodiak Sciences (NASDAQ:KOD) is set to present a series of clinical and preclinical advances at the American Uveitis Society (AUS) and the Association for Research in Vision and Ophthalmology (ARVO) annual meetings between May 2 and May 7, 2026.
